Scientific Validation for Longevity Products
We help producers of supplements, vitamins, cosmetics, and medical devices validate their longevity claims with cutting-edge science.
Our proprietary biological age clock enables you to demonstrate product efficacy with quantitative, clinically robust evidence - giving you the scientific credibility needed for regulators, investors, and consumers.
Technology behind EPIX AI
Our platform advances beyond existing methylation clocks by improving the DeepMAge model with higher accuracy and clinical reliability.
- Precision - Median absolute error reduced from 2.77 to 2.06 years
- Scale - Deep neural networks trained on 7,700 samples across ~1,000 CpGs
- Depth - Run on the high-resolution Illumina EPIC v2 chip (covering 930,000 CpGs) for unmatched biological detail
- Reliability - Sensitive, reproducible, and clinically relevant measurements of biological aging
This technology enables us to deliver results that are both scientifically rigorous and commercially powerful.
Why EPIX AI's Clock Is Different
DNA methylation clocks like EPIX AI are recognized as:
○ Early-response biomarkers, detecting changes before traditional markers
○ Mechanistically tied to core hallmarks of aging (e.g., inflammation, cellular senescence, DNA repair)
○ Sensitive and actionable tools to determine whether interventions can slow, halt, or reverse aging
This means your products can be backed by clear, scientific proof. Not just marketing claims.
Strategic Value for Your Business
By collaborating with EPIX AI, your company gains more than just trial data:
➤ Clinical Proof: Robust evidence to strengthen marketing, regulatory, and investor narratives
➤ Novel Biomarker Insights: Expand your IP portfolio and open doors for publications
➤ Market Differentiation: Position your business as a scientific leader in the longevity and personalized wellness markets
➤ Personalization: Future potential for individual supplement response insights to DNA methylation signatures
Pharma & CRO Clinical Trials
Transform Clinical Trials with Precision Genetic and Epigenetic Testing
Leverage Whole Genome Sequencing (WGS) and 930k CpG Methylation Arrays to optimize patient selection, enhance drug analytics, and uncover deeper patient insights.
Epix AI empowers CROs and pharmaceutical companies to accelerate clinical development with data-driven precision and multi-omics intelligence.
The Clinical Trial Challenge
Clinical trials face growing complexity, rising costs, and delayed approvals. Epix AI addresses these key bottlenecks:
◎ High Failure Rates: Nearly 90% of Phase II/III trials fail due to efficacy issues or patient heterogeneity.
◎ Patient Selection Pitfalls: Recruiting non-responders can cost up to $2.6 billion per drug.
◎ Analytics Gaps: Conventional biomarkers miss epigenetic drivers of drug response.
◎ Limited Patient Insights: Lack of multi-omics data obscures true drug utility and personalization potential.
.png)
Our Precision Testing Solutions
🧬 Whole Genome Sequencing (WGS)
Identifies SNPs, indels, & structural variants linked to drug metabolism and treatment response
(e.g., CYP450 genes).
🧫 930k CpG Methylation Array
Maps genome-wide epigenetic patterns as dynamic biomarkers of disease state and therapy sensitivity.
⚙️ End-to-End Service
From sample processing to trial-ready reports, scalable for cohorts of 50 to 1,000+ with a 8-10 week turnaround.
Applications for Clinical Trials
1. Better Patient Selection
Pre-screen participants with WGS and methylation data to stratify patients by biomarkers, reducing screen failures by 30–50% and accelerating enrollment.
In CNS tumor trials, methylation arrays correctly classified 80% of ambiguous cases for targeted recruitment.
Metric
Enrollment Speed
Responder Enrichment
Cost Savings
Without Testing
6-9 months
Baseline
N/A
With WGS + Methylation
3-4 months
+40%
20-30%
2. Improved Drug Analytics
Longitudinal WGS and methylation tracking refine PK/PD models, capturing drug-induced epigenetic changes.
In breast cancer trials, epigenetic drugs combined with chemotherapy doubled response rates in methylated subgroups.
3. Deeper Patient Understanding
Epigenetic signatures uncover responsive subgroups, enhancing real-world evidence and companion diagnostics.
Why Partner with Epix AI?
○ Cost Savings: 25–40% reduction in trial costs via enriched patient cohorts
○ Faster Results: 2–3x faster path to pivotal data
○ Regulatory Edge: Epigenetic biomarkers support personalized medicine claims
○ Partnership Benefits: Co-branded reports, joint publications, and collaborative validation studies
Seamless Integration
Epix AI integrates effortlessly into existing CRO and Pharma workflows::
➤ Compatibility: API integration with Veeva, Oracle, and other EDC systems
➤ Compliance: Fully CLIA/CAP compliant
➤ Pilot Program: Start with a free proof-of-concept for 20 samples
Ready to Transform Your Clinical Trials?
Partner with Epix AI to unlock precision patient selection and deeper drug insights with advanced multi-omics testing and science-backed data.
The EPIX AI Approach
We conduct targeted clinical trials with up to 60 participants, measuring biological age at three key points:
◎ Baseline before treatment
◎ After 3 months of product use
◎ 3 months after that without treatment
Our unique design not only proves whether a product reduces biological age but also shows whether the effect is sustained or reversible.
Work with EPIX AI
We provide end-to-end support, including:
🧬 Clinical trial design
🧬 Biomarker and DNA methylation analysis
🧬 Statistical evaluation and interpretation
🧬 Full scientific reports + concise executive summaries (tailored for R&D, regulatory submissions, investors, and marketing teams)
Get in touch with us to validate your longevity claims with science.
